Project Grant R01CA303489
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $661K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Cancer Institute awarded the University of Wisconsin - Madison $650,369 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted immunostimulatory dual drug conjugates for treating metastatic castration-resistant prostate cancer. The award funds research into radioimmunostimulants that co-deliver two therapeutic payloads with different mechanisms of action. The research addresses a critical clinical gap: approximately 33 percent of...
- The National Cancer Institute awarded Northwestern University $496,357 under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, to investigate mechanisms of immunosuppression in glioblastoma and develop therapeutic interventions targeting tumor-associated macrophage polarization. The research centers on the peri-necrotic niche within IDH-wildtype glioblastoma tumors, where hypoxic glioma cells and immunosuppressive tumor-associated macrophages aggregate in spatial...
- The National Cancer Institute awarded Washington University $562,550 on July 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop neoantigen-based spherical nucleic acid immunotherapeutics for triple negative breast cancer. The award funds development of a patient-specific nanoparticle immunotherapeutic, termed P-SNA, through an academic-industrial partnership between FlashPoint Therapeutics and the Gillanders Laboratory at Washington University School of Medicine. The...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded University of Wisconsin–Madison $634,791 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) for development of shark antibody radiopharmaceuticals (SHARPs) targeting lineage plasticity in castration-resistant prostate cancer. The funded work develops bispecific antibody constructs that engage two antigens simultaneously to overcome treatment...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute awarded Northwestern University a $1.139 million Cooperative Agreement (UG1CA308665) on April 28, 2026, under the Cancer Treatment Research program (CFDA 93.395) to serve as a Lead Academic Participating Site within the NCI National Clinical Trials Network. The Robert H. Lurie Comprehensive Cancer Center at Northwestern will drive innovation in cancer clinical trials, particularly early-phase and multi-center studies, while expanding access to treatments across...
- This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
- The National Cancer Institute awarded the University of Pittsburgh $658,492 on March 18, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a novel targeted combinatorial therapy for castration-resistant prostate cancer. The award funds research into hyaluronic acid-based nanocarriers co-loaded with the CHK1 inhibitor SRA737 and the WEE1 inhibitor AZD1775 for targeted treatment of advanced castration-resistant prostate cancer (ACRPC), including crpc-adeno and nepc...
- The National Cancer Institute awarded The University of Chicago $518,151 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate nicotinamide N-methyltransferase (NNMT) inhibition as a strategy to sensitize ovarian and colorectal cancers to immune checkpoint inhibitors. The award funds research targeting NNMT expression in cancer-associated fibroblasts within the tumor microenvironment. The project will investigate whether NNMTI'960, a small-molecule NNMT...
- The National Cancer Institute awarded the University of Wisconsin–Madison $113,766 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research combining antigen-specific vaccination with radiopharmaceutical therapy to enhance anti-tumor immunity against metastatic castration-resistant prostate cancer. The project investigates combined treatment using an anti-tumor vaccine to prime tumor-specific CD8+ T cells, followed by radiopharmaceutical therapy targeting...